Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
Curing disease with CRISPR with Trevor Martin from Mammoth Biosciences

From TechCrunch

By Rebecca Szkutak

April 18, 2023

Curing disease with CRISPR with Trevor Martin from Mammoth Biosciences

Welcome back to Found, where we get the stories behind the startups.

This week Darrell and Becca are joined by Trevor Marti the co-founder and CEO of Mammoth Biosciences, a startup that uses CRISPR to diagnose and find treatments for genetic diseases. Trevor talked about what it is like to build a company surrounding novel tech with one of the scientists credited with creating it. He also talked about the sheer scope of problems this technology can solve and how the company decided where to start. Plus, he talks about how Mammoth thinks about public perception of the tech in an age where there is growing hostility toward science.

Subscribe to Found to hear more stories from founders each week.

Connect with us:

  1. On Twitter
  2. On Instagram
  3. Via email: [email protected]

Curing disease with CRISPR with Trevor Martin from Mammoth Biosciences by Rebecca Szkutak originally published on TechCrunch

Most Recent

Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation

Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation

The de-extinction startup is looking to double or triple its previous valuation, according to the report.

Jul 20, 2026

Natural raises $30M to reinvent payments for AI agents — and take on Stripe

Natural raises $30M to reinvent payments for AI agents — and take on Stripe

The one-year-old startup aims to reinvent financial architecture for autonomous AI transactions.

Jul 20, 2026

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

AI infrastructure company Infinity announced Monday a $15 million raise at a $100 million valuation from investors including Touring Capital, Principal VC, and researchers from companies such as OpenAI and Anthropic.

Jul 20, 2026

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

For the first time since 2024, StrictlyVC is coming back to New York City — and we're bringing the kind of access you’d expect from an under-wraps event to the whole startup, VC, and dealmaking community.

Jul 20, 2026

Similar Posts

Cultured meat firm resurrects woolly mammoth in lab-grown meatball

Cultured meat firm resurrects woolly mammoth in lab-grown meatball

Truth, as the saying goes, is often stranger than fiction. The very notion of resurrecting the long-extinct woolly mammoth was the stuff of fantasy not that long ago, but scientists are already working on ways to achieve something close to that, using DNA from soft-tissue in frozen mammoth remains and meshing it with that of […]

Mar 28, 2023

Making more mammoths with Ben Lamm from Colossal

Making more mammoths with Ben Lamm from Colossal

Welcome back to Found, where we get the stories behind the startups. This week Darrell and Becca are joined by Ben Lamm, the founder and CEO of Colossal, a genetics startup that looks to bring extinct species back to life to help with environmental conservation efforts. Ben talked about how he got to this point […]

Mar 21, 2023

The academic to founder pipeline with Dr. Stacy Blain from Concarlo Therapeutics

The academic to founder pipeline with Dr. Stacy Blain from Concarlo Therapeutics

Welcome back to Found, where we get the stories behind the startups. This week, Becca and Dom are joined by Stacy Blain, the co-founder and chief science officer at Concarlo Therapeutics. Blain talked about how she had been researching how to cure drug-resistant cancers before she accidentally found her way into entrepreneurship after her academic […]

May 30, 2023

Promise Bio exits stealth backed by Pfizer and AstraZeneca

Promise Bio exits stealth backed by Pfizer and AstraZeneca

The first thing Promise Bio CEO Ronel Veksler wants you to know about the biotech company he co-founded is that it’s not another AI drug discovery company. Instead, he’s looking to bring precision medicine to autoimmune diseases. Tel Aviv-based Promise Bio has developed a cloud-based AI platform that can spot different Post-Translational Modifications (PTMs) in proteins from a single blood sample. Before Promise’s tech, checking for one of these 200 protein modifications would require individua

Oct 23, 2024

Most Recent

Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation

Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation

The de-extinction startup is looking to double or triple its previous valuation, according to the report.

Jul 20, 2026

Natural raises $30M to reinvent payments for AI agents — and take on Stripe

Natural raises $30M to reinvent payments for AI agents — and take on Stripe

The one-year-old startup aims to reinvent financial architecture for autonomous AI transactions.

Jul 20, 2026

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

AI infrastructure company Infinity announced Monday a $15 million raise at a $100 million valuation from investors including Touring Capital, Principal VC, and researchers from companies such as OpenAI and Anthropic.

Jul 20, 2026

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

For the first time since 2024, StrictlyVC is coming back to New York City — and we're bringing the kind of access you’d expect from an under-wraps event to the whole startup, VC, and dealmaking community.

Jul 20, 2026

Similar Posts

Cultured meat firm resurrects woolly mammoth in lab-grown meatball

Cultured meat firm resurrects woolly mammoth in lab-grown meatball

Truth, as the saying goes, is often stranger than fiction. The very notion of resurrecting the long-extinct woolly mammoth was the stuff of fantasy not that long ago, but scientists are already working on ways to achieve something close to that, using DNA from soft-tissue in frozen mammoth remains and meshing it with that of […]

Mar 28, 2023

Making more mammoths with Ben Lamm from Colossal

Making more mammoths with Ben Lamm from Colossal

Welcome back to Found, where we get the stories behind the startups. This week Darrell and Becca are joined by Ben Lamm, the founder and CEO of Colossal, a genetics startup that looks to bring extinct species back to life to help with environmental conservation efforts. Ben talked about how he got to this point […]

Mar 21, 2023

The academic to founder pipeline with Dr. Stacy Blain from Concarlo Therapeutics

The academic to founder pipeline with Dr. Stacy Blain from Concarlo Therapeutics

Welcome back to Found, where we get the stories behind the startups. This week, Becca and Dom are joined by Stacy Blain, the co-founder and chief science officer at Concarlo Therapeutics. Blain talked about how she had been researching how to cure drug-resistant cancers before she accidentally found her way into entrepreneurship after her academic […]

May 30, 2023

Promise Bio exits stealth backed by Pfizer and AstraZeneca

Promise Bio exits stealth backed by Pfizer and AstraZeneca

The first thing Promise Bio CEO Ronel Veksler wants you to know about the biotech company he co-founded is that it’s not another AI drug discovery company. Instead, he’s looking to bring precision medicine to autoimmune diseases. Tel Aviv-based Promise Bio has developed a cloud-based AI platform that can spot different Post-Translational Modifications (PTMs) in proteins from a single blood sample. Before Promise’s tech, checking for one of these 200 protein modifications would require individua

Oct 23, 2024